Anch red in technology developed at Boston Children's Hospital, NIDO is a medical device company developing SEPIA - an innovative solution for epicardial ablation of ventricular tachycardia (VT). The firm having been co-founded by Chairman of Cardiovascular Surgery and Professor at Harvard Medical School in partnership with the Medical Director for Surgicals Portfolio at Pfizer, SEPIA is designed to allow real-time visualization of the epicardial surface and provide angle and force control to an ablation catheter. Ultimately, the expectation is that it could reduce complications and improve ablation efficiency, leading to decrease recurrence of VT. Effectively bri nging laparoscopic-type minimally-invasive techniques to heart surgery, the device enables direct visualization and surgery on a beating heart through a small incision in the chest; thus avoiding the need for open-heart surgery and the potentially serious neurological side effects of cardiopulmonary bypass.
